Inspirata and Fujifilm Corporation have signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx digital pathology technology, employees and customers, building off the proven success of the established partnership between the companies in UK and Europe.
This agreement will allow Inspirata’s digital pathology business to flourish with a partner who has the breadth, depth and resources required to take the Dynamyx platform to the next stage of its growth and international expansion.
Dynamyx is an open, vendor-agnostic, end-to-end digital pathology solution. Dynamyx’s software capabilities include using whole-slide images from multiple scanning vendors to create an easier path for more pathology laboratories to digitise and realise the benefits of faster patient results, centralised imaging records, and enterprise access to images for all clinicians. Dynamyx will become part of Fujifilm’s Synapse Enterprise Imaging portfolio – an award-winning suite of healthcare IT solutions that unify imaging, data access and workflows across the health system. With the addition of digital pathology, Fujifilm will offer one of the most comprehensive enterprise imaging portfolios on the market. Future releases of Dynamyx will also create opportunities for Fujifilm to support pharmaceutical and contract research organizations with toxicity testing data management for drug development.
The strategic transaction also adds significant tailwinds behind Inspirata’s ongoing focus to become the leading provider of cloud-based, enterprise software as a service (SaaS) solutions for oncology informatics – its main strategic pillar of growth. Critical workflows in oncology informatics, such as clinical trial matching and cancer registry reporting and data abstraction, are ripe for disruption through the powerful and clinically optimised AI and NLP (natural language processing) technology that Inspirata has been developing over two decades.
In 2023, Inspirata will focus its resources on further enhancing and developing its proprietary, purpose-built AI / NLP-enabled technology to support its growing customer base match larger and more diverse portions of their cancer patient populations to the most relative clinical trials in real time. The company will also continue its long-standing service of dozens of central state registries and hundreds of hospital cancer registries, who use Inspirata’s solutions to automate clinical data abstraction for cancer casefinding and reporting, representing one of the largest implementations of AI in the oncology informatics field.
“This landmark transaction is significant for both the future of digital pathology and the fulfilment of Inspirata’s growth strategy in cancer informatics. We strongly believe the Dynamyx solution and team responsible for building its advanced digital pathology workflow will find a great new home within Fujifilm’s Synapse Enterprise Imaging portfolio. We are confident our partners at Fujifilm will build on Dynamyx’s storied legacy and continue to be a driving force behind digitisation in the healthcare imaging space,” says Satish Sanan, Chairman and CEO of Inspirata, Inc.
“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” says Teiichi Goto, President and CEO, representative director, Fujifilm Corporation. “We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitisation and advancement of healthcare.”
Timing for the completion of the transaction is subject to closing conditions and is scheduled for early 2023. Terms of the agreement have not been disclosed.
